IL-2 therapy

San Francisco, California, USA | March 20, 2026 Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin,...

WATERTOWN, Mass., October 8, 2025 — Werewolf Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...